Roche Aktie

311,25EUR
+2,65EUR
+0,86%
20.05.2022
319,70CHF
+2,80CHF
+0,88%
20.05.2022

WKN: 855167 / ISIN: CH0012032048

  Kaufen  
Verkaufen
oder
Werbung

Roche Aktien News

12.05.22Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure (GlobeNewswire)
11.05.22[Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer (GlobeNewswire)
10.05.22Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028 (GlobeNewswire)
29.04.22New three-year data for Roche’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA) (GlobeNewswire)
25.04.22Roche bestätigt Ausblick und will die Dividende weiter anheben (MyDividends)
25.04.22[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem Verkaufswachstum im ersten Quartal 2022 (GlobeNewswire)
22.04.22CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer (GlobeNewswire)
22.04.22CHMP recommends EU conditional approval of Roche’s potential first-in-class bispecific antibody mosunetuzumab for people with relapsed or refractory follicular lymphoma (GlobeNewswire)
05.04.22Roche to showcase the future of diagnostic solutions at EuroMedLab, 10 to 14 April 2022 Munich at ICM International Congress Center (PR Newswire)
05.04.22Roche to showcase the future of diagnostic solutions at EuroMedLab, 10 to 14 April 2022 Munich at ICM International Congress Center (PR Newswire)
04.04.22U.S. FDA grants priority review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults (GlobeNewswire)
04.04.22New data for Roche’s OCREVUS (ocrelizumab) show benefit in disability progression and cognitive decline in both secondary progressive and primary progressive multiple sclerosis (GlobeNewswire)
30.03.22Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer (GlobeNewswire)
25.03.22CHMP recommends EU approval of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma (GlobeNewswire)
25.03.22Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting (GlobeNewswire)
25.03.22Roche announces collaboration with Bristol Myers Squibb to advance personalised healthcare through digital pathology solutions (PR Newswire)
25.03.22Roche announces collaboration with Bristol Myers Squibb to advance personalised healthcare through digital pathology solutions (PR Newswire)
23.03.22Roche donates additional medicines and diagnostics for Ukraine (GlobeNewswire)
16.03.22Roche provides molecular testing solutions to identify and differentiate SARS-CoV-2 Omicron variants of concern (GlobeNewswire)
16.03.22New data for Roche’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA) (GlobeNewswire)
15.03.22Roche Annual General Meeting 2022 (GlobeNewswire)
15.03.22Roche Generalversammlung 2022 (GlobeNewswire)
08.03.22Roche to present new Evrysdi data at MDA 2022 and highlight expanding neuromuscular disease portfolio (GlobeNewswire)
03.03.22Improving Alberta's patient care: Alberta Precision Laboratories and Roche Diagnostics join forces to ensure accurate diagnosis and time saving through provincial integration and standardization o... (PR Newswire)
03.03.22Improving Alberta's patient care: Alberta Precision Laboratories and Roche Diagnostics join forces to ensure accurate diagnosis and time saving through provincial integration and standardization o... (PR Newswire)
02.03.22Roche announces donation of essential medicines to Ukraine (GlobeNewswire)
23.02.22Roche expands the COVID-19 PCR test portfolio to the new cobas 5800 System in countries accepting the CE Mark (PR Newswire)
23.02.22Roche expands the COVID-19 PCR test portfolio to the new cobas 5800 System in countries accepting the CE Mark (PR Newswire)
11.02.22
WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19 (Roche Holding AG)
11.02.22
WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19 (Roche)
11.02.22WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19 (GlobeNewswire)
11.02.22New two-year data for Roche’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss (GlobeNewswire)
11.02.22
New two-year data for Roche’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss (Roche)
11.02.22
New two-year data for Roche’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss (Roche Holding AG)
03.02.22Roche erhöht die Dividende das 35. Jahr in Folge (MyDividends)
03.02.22
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021 (Roche Holding AG)
03.02.22
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem Jahresergebnis 2021 (Roche)
03.02.22[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021 (GlobeNewswire)
03.02.22[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem Jahresergebnis 2021 (GlobeNewswire)
01.02.22
Changes to the Roche Board of Directors and the Corporate Executive Committee (Roche Holding AG)
Seite: 123456789...14

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.
Werbung
finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln